Search

everythinglearnresearchcommunity

for

Search:↓

A user experienced hair retention but sexual side effects after using dutasteride for a year. Others shared similar experiences with finasteride and dutasteride, suggesting consulting a doctor for persistent issues.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

The conversation discusses the use of dutasteride (0.5 mg daily) for hair loss, with additional treatments like minoxidil, derma rolling, and nizoral shampoo. The user reports positive progress over two years with no significant side effects, emphasizing the importance of consistency and patience.

Pyrilutamide is being discussed as an alternative for those who can't use finasteride, but users report it may be ineffective at low concentrations. Some users are combining it with minoxidil, microneedling, and other treatments, but results vary.

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

It's safe to take oral dutasteride with pyrilutamide, as many use 5-alpha-reductase inhibitors with topical antiandrogens for better results. Avoid ingesting pyrilutamide.

Dutasteride can be taken daily or weekly, depending on individual goals and side effect tolerance. Daily use maximizes suppression, while less frequent dosing reduces side effects.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

A user experienced hairline improvement after four weeks on 1.5mg dutasteride but had side effects like reduced libido and sensitive nipples. They plan to switch to finasteride to manage these side effects.

People are discussing hair loss treatments, including pyrilutamide, minoxidil, dutasteride, alfatradiol, and bimatoprost. Users share their experiences and side effects, noting that pyrilutamide is considered more effective and safer than RU58841.

OP developed hives after using Kx 826 (Pyrilutamide) 1% twice daily for 3 weeks. The hives appeared on the arms, chest, and groin area.

The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

A user taking dutasteride and minoxidil for hair loss is considering adding RU58841 to their regimen due to unsatisfactory results. Other users suggest alternatives and discuss the potential temporary benefits and limitations of RU58841.

A user shared their 2-year progress using finasteride every other day with no side effects. Others discussed their experiences, shedding cycles, and patience with the treatment.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

The conversation discusses the use of spironolactone, cyproterone acetate, and bicalutamide for hair loss, with concerns about side effects like gynecomastia and depression. Topical spironolactone is considered safe for men and effective when combined with regular treatments.

A user who has been using Pyrilutamide for 5 months with no results, and other users suggesting they switch to RU58841 or stick to their treatment plan for at least one year.

The conversation discusses the possibility and safety of adding minoxidil sulfate to mesotherapy with dutasteride. Users are inquiring if anyone has tried this combination.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

Switching from daily 0.5mg dutasteride to three times a week may reduce side effects without worsening hair loss. Bloodwork showed no abnormalities, supporting the change.

A user in the UAE is facing customs issues with ordering Fluridil (Eucapil) and is considering ordering smaller quantities or switching to Pyrilutamide. They are also using finasteride daily to maintain hair and are unsure of Fluridil's effectiveness.

The conversation is about accessing and purchasing RU58841 or Pyrilutamide for hair loss treatment, with mentions of alternatives like Breezula. Users discuss price differences in various countries and suggest websites like rudirect.com for purchasing.

A 22-year-old switched from finasteride to dutasteride for hair loss treatment, also using RU58841, and is managing hypothyroidism. Despite ongoing shedding, they report some improvement and plan to continue dutasteride for a year before considering minoxidil.

The user has been using finasteride for hair loss and is considering adding RU58841. They ask about RU58841's effectiveness, potential heart side effects, duration of action, dosage increase over time, transitioning to GT20029, and where to find the liquid form.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

A 27-year-old male experienced hair thickening using a specialized pill containing Dutasteride and Minoxidil, despite taking it irregularly due to being away from home. He plans to resume a more regular dosing schedule for better results, as he noticed side effects like brain fog and decreased libido.